Kentucky Retirement Systems Sells 393 Shares of Insulet Co. (NASDAQ:PODD)

Kentucky Retirement Systems reduced its holdings in Insulet Co. (NASDAQ:PODD) by 7.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,885 shares of the medical instruments supplier’s stock after selling 393 shares during the period. Kentucky Retirement Systems’ holdings in Insulet were worth $1,137,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Blue Trust Inc. boosted its position in shares of Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 58 shares during the last quarter. International Assets Investment Management LLC bought a new position in Insulet during the second quarter worth about $32,000. Venturi Wealth Management LLC grew its position in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 133 shares during the period. UMB Bank n.a. increased its stake in shares of Insulet by 81.0% in the 2nd quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after acquiring an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its position in shares of Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after acquiring an additional 145 shares during the period.

Analyst Ratings Changes

PODD has been the subject of a number of analyst reports. Citigroup boosted their price objective on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. BTIG Research increased their price target on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Canaccord Genuity Group lifted their price objective on Insulet from $236.00 to $269.00 and gave the company a “buy” rating in a report on Wednesday, September 25th. UBS Group boosted their price objective on Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Finally, Sanford C. Bernstein started coverage on shares of Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Price Performance

Shares of NASDAQ PODD opened at $260.68 on Tuesday. The stock has a market capitalization of $18.28 billion, a price-to-earnings ratio of 44.64, a PEG ratio of 3.98 and a beta of 1.22. The business has a 50-day moving average of $238.60 and a 200-day moving average of $208.60. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $279.40.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.